Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Rhea-AI Summary

Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and COO James Schaub will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will be available on demand and can be accessed through a webcast link provided in the announcement. Osmotica specializes in developing products for underserved markets and launched UPNEEQ for treating droopy eyelids in September 2020. The webcast will be archived for 30 days on the company's website.

BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows:

Date:	Monday, September 13, 2021
Time:	On Demand
Webcast:	https://journey.ct.events/view/2feb327a-ca2a-4226-806e-84a8a49480db

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.

About Osmotica Pharmaceuticals plc

Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations. In July 2020, the Company received regulatory approval from the U.S Food and Drug Administration for RVL-1201, or UPNEEQ^® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults. UPNEEQ was commercially launched September 2020 through RVL Pharmaceuticals, Inc., the Company’s ophthalmic subsidiary, to a limited number of eye care professionals with commercialization operations expanded in 2021 among ophthalmology, optometry and oculoplastic specialties.

Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com

FAQ

When is Osmotica Pharmaceuticals presenting at the H.C. Wainwright conference?

Osmotica Pharmaceuticals will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021.

Who will represent Osmotica Pharmaceuticals at the investment conference?

CEO Brian Markison and COO James Schaub will represent Osmotica Pharmaceuticals at the conference.

How can I watch Osmotica Pharmaceuticals' presentation?

Osmotica's presentation will be available on demand via a webcast accessible through their announcement.

What product did Osmotica Pharmaceuticals launch in September 2020?

Osmotica launched UPNEEQ, an ophthalmic solution for treating droopy eyelids, in September 2020.

Where can I find the archived webcast of Osmotica Pharmaceuticals' presentation?

The archived webcast of Osmotica Pharmaceuticals' presentation will be available on their website for 30 days after the event.